HAYWARD, Calif. (PRWEB) October 15, 2020
Predicine, a molecular insights company headquartered in Hayward, California, today announced that it will host a satellite symposium at the 2020 International Society of Liquid Biopsy (ISLB) Virtual Congress, to be held on October 30, 2020. The symposium entitled “cfDNA and cfRNA: A New Paradigm in Clinical Trials, MRD, and Early Cancer Detection” will discuss the clinical utility of circulating cell-free DNA and RNA liquid biopsy tests with a focus on MRD and early cancer detection.
This symposium will bring together biomarker experts, Dr. Jürgen Scheuenpflug, Global Head Clinical Biomarkers & Companion Diagnostics and Executive Director, Translational Medicine at Merck KGaA and Dr. Andrew Davis, Assistant Professor, Medical Oncology at Washington University School of Medicine in St. Louis, and Reed Selby, Director of Business Development at Predicine Inc. They will share their experience in using Predicine’s comprehensive liquid biopsy solution in clinical trials, patient care, MRD, and early cancer detection.
Symposium title: cfDNA and cfRNA: A New Paradigm in Clinical Trials, MRD, and Early Cancer Detection
Date: Friday, October 30, 2020
Time: 1:30PM CET / 7:30AM EST / 4:30AM PST
Assessment of the Clinical Utilities of Blood TMB Through Simultaneous Multi-parametric Profiling of cfRNA and ctDNA in Advanced-stage Colorectal Cancer
Jürgen Scheuenpflug, PhD, Global Head Clinical Biomarkers & Companion Diagnostics and Executive Director, Translational Medicine at Merck KGaA
Liquid Biopsy: The Path Toward Clinical Utility
Andrew Davis, MD, Assistant Professor, Medical Oncology at Washington University School of Medicine in St. Louis
cfDNA and cfRNA Solutions Across the Continuum of Care in Global Clinical Trials
Reed Selby, Director, Business Development at Predicine, Inc.
Register for the symposium: link.